Ben Hsieh
About Ben Hsieh
Ben Hsieh is the Co-Founder and R&D Director at Cellmax Life, where he has worked since 2013, focusing on microfluidic device fabrication and system automation. He has a strong background in biochemical engineering and has contributed to significant advancements in cancer detection through research and development.
Work at CellMax Life
Ben Hsieh serves as Co-Founder and R&D Director at CellMax Life, a position he has held since 2013. In this role, he guides research and development activities with a focus on microfluidic device fabrication and system automation. He has been instrumental in building a clinical test lab in Taiwan, which supports international research and development operations. Hsieh is also involved in writing grant proposals to secure funding for various research projects at the company. His efforts contribute to the establishment and growth of CellMax Life within the biotech industry.
Education and Expertise
Ben Hsieh holds a Ph.D. and MSc in Biochemical Engineering from the University of California, Irvine, where he studied from 1993 to 1998. He also earned a Bachelor of Science in Chemical Engineering with a Life Sciences Concentrate from National Tsing Hua University between 1987 and 1991. His educational background provides a strong foundation for his expertise in microfluidic device fabrication and cancer detection technologies. Hsieh's academic training supports his ongoing research in circulating tumor cells and their applications in early cancer detection.
Background
Prior to his role at CellMax Life, Ben Hsieh worked as a Postdoctoral Research Scientist at Lawrence Berkeley National Laboratory from 1998 to 2001. This experience contributed to his extensive knowledge in research methodologies and scientific inquiry. His career trajectory reflects a commitment to advancing cancer detection technologies and enhancing research capabilities in the biotech sector.
Achievements
Ben Hsieh has made significant contributions to the field of cancer detection through his involvement in the development and clinical validation of blood tests for early detection of colorectal adenomas and cancer. He has participated in the ASCO Gastrointestinal Cancers Symposium and has worked on a novel circulating tumor cell assay for colorectal cancer detection. Hsieh has also contributed to multiple publications focused on cancer detection and blood tests, enhancing the scientific community's understanding of these critical areas.
Research and Development Contributions
At CellMax Life, Ben Hsieh plays a key role in expanding the company's patent portfolio by collaborating closely with patent attorneys. His research efforts include analytical validation of the CellMax platform for early cancer detection and investigations into circulating tumor cells' roles in cancer detection. These contributions are vital for advancing the company's technological capabilities and intellectual property assets.